Evopoint Biosciences Inc.
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | Claudin 18.2 (CLDN18.2)Antibody–drug conjugate | Non-Small Cell Lung CancerGastric Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
Financial reports
No financial reports recorded.